# GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")
Canonical URL: https://biopharmsignal.com/news/GRI/gri-bio-reports-full-year-2024-financial-results-and-reiterates-expected-clinical-data-readouts-in-2025-for-ongoing-phase-2a-study-of-gri-0621-in-idiopathic-pulmonary-fibrosis-ipf
Ticker: GRI
Company: GRI Bio
Source: GRI Bio
Published: 2025-03-17 08:05 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em> Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively </em></p> <p align="center"><em>Cash runway expected

## Article Body
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively

Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621

LA JOLLA, CA, March  17, 2025  (GLOBE NEWSWIRE) --...
## Recent Company News
- 2026-06-18 13:31 EST — [GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis](https://biopharmsignal.com/news/GRI/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathi-36c7f058) — Source: GRI Bio
- 2026-05-14 08:35 EST — [GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline](https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-immune-modulating-pipeline) — Source: GRI Bio
- 2026-04-08 08:30 EST — [GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions](https://biopharmsignal.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions) — Source: GRI Bio
- 2026-02-17 09:15 EST — [GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment](https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-featured-in-virtual-investor-what-this-means-segment) — Source: GRI Bio
- 2026-02-05 09:15 EST — [GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial](https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial) — Source: GRI Bio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)